



**FOR IMMEDIATE RELEASE**

**CYTOO Cell Architects announces three patent license agreements and introduces its first products for the life science research market**

***CYTOO has worldwide exclusivity for adhesive cell micropattern technology and launches their CYTOOchips™.***

**Grenoble, April 27, 2009.** CYTOO Cell Architects has entered into an exclusive worldwide license agreement for the adhesive micropattern patent portfolio from the Curie Institute and the CNRS. The company has also solidified its freedom to operate commercially with signed patent license agreements with the CEA (Life Sciences Division) and Harvard University. Following execution of these licenses, CYTOO immediately launched the CYTOOchips as its first product on the research market.

The successful execution of these license agreements was a major milestone in the evolution of the young Company. The intellectual property of these prestigious research institutes allows CYTOO to commercialize adhesive micropatterns for cell analysis worldwide. With exclusive patent rights from the Curie Institute and CNRS, CYTOO is in a strong position to assume a leadership role in the fields of cell analysis and high content screening.

In January 2009, CYTOO moved into new facilities at MINATEC®, Grenoble. CYTOO's operations comprise 300m<sup>2</sup> of clean rooms, labs and offices and the Company has quickly grown to a team of 7 highly skilled individuals dedicated to R&D and production operations. Earlier this year, the Company established a pilot production line and manufactured its initial batches of CYTOOchips. The technology was validated through work completed at 16 beta test laboratories throughout Europe, the USA and Japan. Results from the beta sites confirmed excellent potential for the adhesive micropatterns in a wide range of cell biology applications.

CYTOOchips can be ordered through the CYTOO website ([www.cytoo.com/store](http://www.cytoo.com/store)) and are 4cm<sup>2</sup> glass coverslips bearing over 20,000 adhesive micropatterns for individual cells. The proprietary CYTOOchips are the first tools commercially available for cell screening and analysis which normalize cell morphology and behavior. They are designed for research and development of cell assays, carried out by more than 180,000 professionals worldwide. Available in a "plug 'n play" format, CYTOOchips offer researchers an immediate substitute for conventional glass coverslips. Micropatterns are available in a wide range of geometries to accommodate most cell types. The Starter's CYTOOchip offers researchers an easy introduction to the technology and makes it possible to compare cell behavior on 12 different micropattern geometries to the standard cell culture surface.

### **About Cytoo SA**

Cytoo SA was incorporated in June 2008 and is based in Grenoble, France. The Company focuses on the development, manufacture and marketing of innovative products primarily focused on applications in cell based assays, high content analysis and cell screening for the life science research market. CYTOO's proprietary micropattern-based products make cellular analysis robust and reliable by dramatically decreasing cell variability. The Company is headed by François Chatelain and Alexandra Fuchs, both former scientists of the CEA. Other members of the Board include Jacques Lewiner, former scientific director of the Paris School ESPCI, Michel Bornens, Research Director and administrator of the Curie Institute, and Celia Hart, a representative member of CEA Valorisation.

### **About The Curie Institute**

The Institut Curie is a state approval foundation, with 2 200 staff members, which has expanded upon the pioneering work of Marie Curie since 1909. It has grown to become the largest dedicated cancer research center in France, pioneering an interdisciplinary approach to research and treatment. The aim of Institut Curie Research Center and Hospital is to transform basic scientific knowledge into new diagnostic, prognostic and therapeutic practices and products as quickly as possible. Institut Curie Research Center, composed of 77 teams including biologists, chemists, physicists and clinicians, works closely with the Hospital, which is the leading European center for breast cancer care, a national reference center for numerous tumors and is currently developing an intensive clinical research program. Working with these clinical and research teams is a special Translational Department which helps implement the transfer of advances from the lab into the hospital or to industry.

### **About The CEA, Life Sciences Division**

The CEA is the French Atomic Energy Commission (Commissariat à l'énergie atomique). It is a public body established in October 1945 by General de Gaulle. A leader in research, development and innovation, the CEA is active in three main fields: Energy, information and health technologies, and defense and national security. In each of these fields, the CEA maintains a cross-disciplinary culture of engineers and researchers, building on the synergies between fundamental and technological research. In 2008, the total CEA workforce consisted of 15 581 employees.

### **Contact :**

François Chatelain, CEO  
CYTOO Cell Architects  
7 parvis Louis Néel - Bat. 52 BP 50  
38040 Grenoble Cedex 09  
+33 (0)4 38 88 47 05  
fchatelain@cytoo.com